Zan is ‘worth’ far more even than that, but it’s far from certain shareholders will pocket the value. It seems perfectly sane and sober to envisage a notional ‘value’ - once clinically validated - larger than the MC of a BP, and well beyond the means of anyone to pay outright. IMO we should be planning not to sell, but to rent out IP as a string of licensing deals with individual BPs.
This is of course not the norm for a rising bio-spec, which is meant to feel ‘amazed’ and grateful at a large buyout. But RAC is not the norm, with potentially far greater shareholder cohesion and hence negotiating options.
Ann: Race releases complete cardio-protection data & video, page-201
-
- There are more pages in this discussion • 27 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.88 |
Change
-0.010(0.53%) |
Mkt cap ! $317.6M | |||
| Open | High | Low | Value | Volume |
| $1.89 | $1.89 | $1.86 | $22.12K | 11.76K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1340 | $1.87 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.88 | 516 | 2 |
View Market Depth
| Last trade - 10.50am 12/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |